CUV
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Clinuvel Pharmaceuticals Limited is a pharmaceutical company focused on developing and commercializing treatments for acute and chronic medical conditions affecting the skin and central nervous system. The company's primary business segment involves the development of melanocortin-based therapies, with its flagship product SCENESSE (afamelanotide) approved for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) in Europe and the United States. Clinuvel is currently advancing clinical programs for vitiligo, including the Phase III study CUV105 and the design of the pivotal CUV107 study, as well as pursuing regulatory approvals for NEURACTHEL Instant for variegate porphyria. The company also operates a PhotoCosmetics segment, offering skincare products such as CYACÊLLE and the M-lines, which utilize the company's expertise in photoprotection and DNA repair. Clinuvel serves markets in North America, Europe, and Latin America, with distribution partners in the U.S., Canada, Colombia, and Argentina. The company was founded in 1999 when an Australian team acquired the rights to afamelanotide, and it lists its American Depositary Shares on the Nasdaq Stock Market.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Pharmaceuticals, Biotechnology & Life Sciences Homepage clinuvel.com
Sector Healthcare IR page clinuvel.com/investor
Tags
photomedicine, melanocortins, erythropoietic protoporphyria, vitiligo, variegate porphyria, photo-cosmetics, peptide drug delivery, central nervous system, skin disorders, rare diseases, SCENESSE, afamelanotide, NEURACTHEL Instant, CYACÊLLE, M-lines, PRÉNUMBRA, VLRX-L, Valentech, Diligens Salud SA
Press page clinuvel.com/investor/asx-announcements

Metrics

Valuation  
Market cap A$ 385.722M
Market cap (USD) $ 259.641M
P/E 10.13
PEG —
P/BV 1.33
P/S 4.37
P/OCF 10.45
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 36.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue — — 88.178M 78.321M — — — — 25.75M 16.985M 6.42M 3.26M 2.527M 1.963M 1.294M 2.276M —
Net profit — — 35.636M 30.605M — — — — 13.224M 7.181M -3.121M -10.398M -5.526M -6.803M -9.767M -11.409M —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Change in substantial holding Bull 0 Bear 0 Routine
Change in substantial holding - Updated Bull 0 Bear 0 Routine
Chair address Bull 0 Bear 0 Routine

Prompts

Clinuvel Pharmaceuticals Limited (ticker CUV), listed in Australia.

Company History

Date Change Detail
— Former tickers CLVLY

ETFs Holding Clinuvel Pharmaceuticals Limited

ETF Weight in ETF Shares Market value As of
AVDS 0.01% 7,426 $ 37.843K Nov 16, 2026
DFIS 0.00% 53,540 $ 278.56K Nov 12, 2026
DFIC 0.00% 46,696 $ 242.952K Nov 12, 2026
DISV 0.00% 8,242 $ 42.882K Nov 12, 2026
DFAI 0.00% 24,698 $ 128.5K Nov 12, 2026
DFAX 0.00% 10,919 $ 56.81K Nov 12, 2026
AVDV 0.00% 484 $ 2,466.50 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
CUV canonical Common share — AU asx 7.24 AUD 2026-11-19
CUVL Common share — US nasdaq 5.96 USD 2026-09-30